G1 believes it has sufficient cash runway to achieve anticipated company profitability in the second half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GTHX:
- G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
- G1 Therapeutics Acquisition and Executive Compensation Revamp
- Pharmacosmos Group to Acquire G1 Therapeutics
- Pharmacosmos Group to acquire G1 Therapeutics for $7.15 per share
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)